The New Game for CDMOs: Shifting from Capacity Scale to Knowledge Capabilities

The pharmaceutical CDMO industry is currently navigating an unprecedented wave of transformation. Over the past two years, multiple industry reports have consistently indicated that the competitive threshold has shifted from “capacity scale” to “the ability to rapidly respond to client needs and maintain technical leadership.” In this changing landscape, collaboration is no longer merely a price war, but a contest of speed, depth of collaboration, and knowledge capabilities (Lavery, 2025; EY, 2025).
Market research points out that AI is becoming the core driver of outsourcing partnerships, reshaping a brand-new collaboration model between CDMOs and pharmaceutical companies (PharmTech, 2025). CDMOs are no longer expected to simply execute production tasks; instead, they are expected to become Knowledge Partners, sharing knowledge, co-constructing technology, and sharing risks with their clients.

This evolution in roles inevitably demands that organizations possess new capabilities: not merely execution, but also analysis, prediction, and innovation. CDMOs have transcended their positioning as simple contract manufacturers, transforming into trusted partners for pharmaceutical companies in the realms of process knowledge and technology.

Centering on the “Knowledge Gap Map”: Initiating a New Dialogue on Value Co-creation

In the midst of this transformation, a pivotal evolution is the shift from a manufacturing outsourcing partner to a “Knowledge Partner.”
In the traditional outsourcing model, dialogues typically revolved around pricing, contracts, and deliverables; however, future partnerships will require jointly identifying technical bottlenecks, aligning assumptions, and establishing R&D consensus with clients right from the start, in order to share the fruits of innovation.

This role demands that CDMOs generate a “Knowledge Gap Map” at the earliest possible stage, enabling both parties to rapidly identify the gaps between existing process technologies and target objectives.
This mechanism allows Business Development (BD) teams and clients to bypass cumbersome document exchanges and repetitive communication, focusing directly on value co-creation. No longer bogged down by administrative paperwork, BD professionals can devote their time to the strategic level of value creation. Simultaneously, clients can deeply appreciate the knowledge value of the service, shifting the collaboration from mere “pricing” to “joint exploration,” “value co-creation,” and “shared success.”

This model of knowledge co-creation is not merely a commercial transaction, but a reshaping of the client relationship: CDMOs are no longer just delivering products, but becoming the power backing their clients, providing the basis for decision-making and technical insights.

Process R&D Transformation: Cross-Disciplinary and Cross-Database Knowledge Integration, Analysis, and Inference

To achieve the transformation into a Knowledge Partner, the core challenge for CDMOs lies in integrating knowledge across disciplines and databases.
Taking antibody therapeutics as an example, projects span multiple fields—including cell biology, protein engineering, gene regulation, and immunology—each with its own independent body of literature and knowledge base. External data (such as clinical data, genomic databases, and published literature) are scattered across multiple repositories, while internal data (such as process parameters, batch records, and analytical reports) often remain siloed. This fragmentation significantly hinders the speed of R&D and innovation.

By implementing proprietary enterprise models, organizations can elevate previously siloed data and knowledge onto a unified plane of comprehension, analysis, and inference.
This integration not only accelerates process technology assessments but also reduces organizational reliance on individual experts, fostering a sustainable and dynamic “Knowledge Circulation.” Once this mechanism is operationalized, a CDMO’s R&D value transcends mere execution, evolving into a dual capability of knowledge synthesis and process implementation.

Founder’s Perspective: Proprietary Enterprise AI Models are the Action Plan for CDMOs to Bridge Profitability and Innovation.

Digital transformation has enabled organizations to amass data and build BI platforms, yet the results often remain confined to ‘viewing the past.’
The key to AI transformation lies in building proprietary enterprise models. These are not merely ‘large repositories of existing global knowledge,’ but engines that synthesize external insights with internal technical expertise. Through reasoning, comparison, and generation, they drive internal automation, analytical inference, and value creation.

Crucially, AI transformation is directly linked to profitability. By shortening contracting cycles, enhancing the client experience, and accelerating drug delivery to market, it ultimately generates a sustainable cycle of profitability for the enterprise.

References

• EY-Parthenon. (2025). How CDMOs are leading innovation for pharmaceutical partners. EY.

• Lavery, P. (2025). Market Demands and Emerging Technologies Shape Outsourcing Models. Pharmaceutical Technology.

• Mareana. (2024, September 7). CDMOs: Gearing Up for the Booming Biopharma Market.

• McKinsey & Company. (2024, January 9). Generative AI in the pharmaceutical industry: Moving from hype to reality.

• OmniaBio. (2025). AI-enabled biomanufacturing innovation enhances process optimization in CGT CDMO. ISCT Global.

• Outsourced Pharma. (2025, June 24). Smarter CDMO Engagement with AI in Biologics and Cell Gene Therapy.

Michael Han

Founder of therapiAI, is dedicated to the frontiers of PharmaTech. In this column, he explores global ADC markets, CDMO digital transformation, and AI innovation. Follow us for expert insights and actionable strategies to navigate the future of healthcare.